Pharmacokinetics of amphotericin B lipid complex in critically ill patients on continuous veno-venous haemofiltration

International Journal of Antimicrobial Agents

Volumn 23, Issue 1, 2004, Pages 80-83

  Bellmann, Romuald ^a   Egger, Petra ^a,b   Djanani, Angela ^a   Wiedermann, Christian J ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY OF TRENTO   (Italy)

Author keywords

Abelcet; ABLC; Amphotericin B lipid complex; Continuous veno venous haemofiltration; Lipid formulated amphotericin B; Pharmacokinetics

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ACUTE KIDNEY FAILURE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG CLEARANCE; HEMOFILTRATION; HUMAN; MALE; MYCOSIS; PRIORITY JOURNAL; SAMPLING; TIME; VENOUS CIRCULATION;

EID: 0346008067     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.05.014     Document Type: Article

References (28)

1. Marsh P.K., Tally F., Kellum J., Callow A., Gorbach S.L. Candida infections in surgical patients. Ann. Surg. 198:1983;42-47.
2. D'Amelio L.F., Wagner B., Azimuddin S., Sutyak J.P., Hammond J.S. Antibiotic patterns associated with fungal colonization in critically ill surgical patients. Am. Surg. 6:1995;1049-1053.
3. Hughes W.T., Armstrong D., Bodey G.et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. 34:2002;730-751.
4. Walsh T.J., Finberg R.W., Arndt C., Hiemenz J., Schwartz C., Bodensteiner D.et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med. 340:1999;764-771.
5. Wingard J.R., Kubilis P., Lee L., Yee G., White M., Walshe L.et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis. 29:1999;1402-1407.
6. Fanos V., Cataldi L. Amphotericin B-induced nephrotoxicity: a review. J. Chemother. 12:2000;463-470.
7. Eriksson U., Seifert B., Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 h: randomised controlled trial. Br. Med. J. 322:2001;579-582.
8. Adler-Moore J.P., Proffitt R.T. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J. Liposome Res. 3:1993;429-450.
9. Boswell G.W., Buell D., Bekersky I. AmBisome (liposomal amphotericin B): a comparative review. J. Clin. Pharmacol. 38:1998;583-592.
10. Ridente Y., Aubard J., Bolard J. Absence in amphotericin B-spiked plasma of the free monomeric drug, as detected by SERS. FEBS Lett. 446:1999;282-286.
11. Wasan K.M., Lopez-Berestein G. Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients. Clin. Infect. Dis. 23:1996;1126-1138.
12. Hiemenz J.W., W J., Walsh T.J. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22:1996;S133-S144.
13. Wong-Beringer A., Jacobs R.A., Guglielmo B.J. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. 27:1998;603-618.
14. De Marie S. Liposomal and lipid-based formulations of amphotericin B, Leukemia 1996;(Suppl 2):S93-6.
15. Adedoyin A., Bernardo J.F., Swenson C.E., Bolsack L.E., Horwith G., DeWit S.et al. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob. Agents Chemother. 41:1997;2201-2208.
16. Adedoyin A., Swenson C.E., Bolcsak L.E., Hellmann A., Radowska D., Horwith G.et al. A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections. Antimicrob. Agents Chemother. 44:2000;2900-2902.
17. Egger P., Bellmann R., Wiedermann C.J. Determination of amphotericin B, liposomal amphotericin B, and amphotericin B colloidal dispersion in plasma by high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 760:2001;307-313.
18. Kan V.L., Bennett J.E., Amantea M.A., Smolskis M.C., McManus E., Grasela D.M.et al. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers. J. Infect. Dis. 164:1991;418-421.
19. Sanders S.W., Buchi K.N., Goddard M.S., Lang J.K., Tolman K.G. Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob. Agents Chemother. 35:1991;1029-1034.
20. Walsh T.J., Whitcomb P., Piscitelli S., Figg W.D., Hill S., Chanock S.J.et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob. Agents Chemother. 41:1997;1944-1948.
21. Lipman J., Scribante J., Gous A.G., Hon H., Tshukutsoane S. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis: the Baragwanath Ciprofloxacin Study Group. Antimicrob Agents Chemother. 42:1998;2235-2239.
22. Frothingham R. Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia. Clin. Infect. Dis. 35:2002;896-897.
23. Tiphine M., Letscher-Bru V., Herbrecht R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl. Infect. Dis. 1:1999;273-283.
24. Janknegt R., de Marie S., Bakker-Woudenberg I.A., Crommelin D.J. Liposomal and lipid formulations of amphotericin B. Clin. Pharmacokinet. 23:1992;279-291.
25. Heinemann V., Bosse D., Jehn U., Kahny B., Wachholz K., Debus A.et al. Pharmacokinetics of liposomal amphotericin B (AmBisome) in critically ill patients. Antimicrob Agents Chemother. 41:1997;1275-1280.
26. Humphreys H., Oliver D.A., Winter R., Warnock D.W. Liposomal amphotericin B and continuous venous-venous haemofiltration. J. Antimicrob. Chemother. 33:1994;1070-1071.
27. Bellmann R., Egger P., Gritsch W., Bellmann-Weiler R., Joannidis M., Kaneider N.et al. Amphotericin B lipid formulations in critically ill patients on continuous veno-venous hemofiltration. J. Antimicrob. Chemother. 51:2003;671-681.
28. Fleming R.V., Kantarjian H.M., Husni R., Rolston K., Lim J., Raad I.et al. Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk. Lymphoma. 40:2001;511-520.